The Irish Times – Zoetis pays $85m for Irish petcare biopharma Nexvet
Please link to the article below by Dominic Coyle which was posted in Apr 2017 by irishtimes.com/business page.
Nexvet, the Irish pet pharmaceutical group, had an unusual structure, with the company conducting its drug discovery in Australia, undertaking clinical trials in the United States and Europe, and manufacturing the drugs in Ireland for sale into international markets. The US animal health company, Zoetis has agreed to pay $6.72 per share through Zoetis Bidco, which values Nexvet at $85m.
You can access further information by reading the full article by clicking on the button below.